نتایج جستجو برای: mantle cell lymphomas

تعداد نتایج: 1700837  

2016
Laura Broutier Marion Creveaux Jonathan Vial Antonin Tortereau Jean‐Guy Delcros Guillaume Chazot Mark J McCarron Sophie Léon Céline Pangault Nicolas Gadot Amélie Colombe Marie‐Laure Boulland Jonathan Blachier Julien C Marie Alexandra Traverse‐Glehen Olivier Donzé Catherine Chassagne‐Clément Gilles Salles Karin Tarte Patrick Mehlen Marie Castets

DCC (Deleted in Colorectal Carcinoma) has been demonstrated to constrain tumor progression by inducing apoptosis unless engaged by its ligand netrin-1. This has been shown in breast and colorectal cancers; however, this tumor suppressive function in other cancers is not established. Using a transgenic mouse model, we report here that inhibition of DCC-induced apoptosis is associated with lympho...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2003
Nicole Y Fang Timothy C Greiner Dennis D Weisenburger Wing C Chan Julie M Vose Lynette M Smith James O Armitage R Aeryn Mayer Brian L Pike Francis S Collins Joseph G Hacia

Mutations have been described in the ataxia telangiectasia mutated (ATM) gene in small numbers of cases of lymphoid neoplasia. However, surveys of the ATM mutation status in lymphoma have been limited due to the large size (62 exons) and complex mutational spectrum of this gene. We have used microarray-based assays with 250,000 oligonucleotides to screen lymphomas from 120 patients for all poss...

Journal: :Blood 2003
Leticia Quintanilla-Martinez Theresa Davies-Hill Falko Fend Julia Calzada-Wack Lynn Sorbara Elias Campo Elaine S Jaffe Mark Raffeld

p27 is a cyclin-dependent kinase inhibitor that plays a critical role in regulating G(1)/S progression, and whose activity is, in part, regulated through interactions with D-type cyclins. Mantle cell lymphoma (MCL) is characterized by the t(11;14) translocation resulting in deregulated cyclin D1. We previously showed that p27 expression in MCL, as assessed by immunohistochemistry (IHC), does no...

2007
Margaret A. Shipp Thomas M. Habermann

The aggressive lymphomas are potentially curable. The natural history of certain aggressive lymphomas has been altered by monoclonal antibody therapy. Targeted monoclonal antibody therapy to the CD20 antigen has altered the outcome of patients with diffuse large B-cell lymphoma in patients of all ages. Anti-CD20–based radioimmunoconjugates are being evaluated as radioimmunotherapy approaches in...

Journal: :The Egyptian journal of immunology 2011
Ahmad Baraka Hatem M Salem

Regulatory T cells (Tregs) play a central role in protecting the host from autoimmune diseases. However, Tregs also pose a major problem to anti-tumor immunity. The expansion and accumulation of these immunosuppressive cells correlate with advanced tumor growth and predict poor disease prognosis. The study aims at evaluation of the clinical role of regulatory T cells in B-cell Non-Hodgkin's lym...

Journal: :Hematological Oncology 2021

In the last years several borderline B-cell lymphoid proliferations have been recognized that lie at interface between benign and malignant. These lesions can be divided in two groups; those considered precursor of well malignancies group indolent lymphomas with limited potential for progression. Precursor are monoclonal share many genetic features their malignant counterpart. The first lesion ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2000
R J Kreitman I Margulies M Stetler-Stevenson Q C Wang D J FitzGerald I Pastan

Chemical conjugates of anti-CD22 monoclonal antibodies and toxins have been used to treat CD22+ hematological malignancies. A new anti-CD22 recombinant immunotoxin RFB4(dsFv)-PE38, composed of the Fv portion of the monoclonal antibody RFB4 fused to a truncated form of Pseudomonas exotoxin A, is being developed to target CD22+ tumor cells. To explore the potential clinical utility of this recomb...

2015
Frank K. Braun Rohit Mathur Lalit Sehgal Rachel Wilkie-Grantham Joya Chandra Zuzana Berkova Felipe Samaniego

Non-Hodgkin lymphomas (NHLs) are characterized by specific abnormalities that alter cell cycle regulation, DNA damage response, and apoptotic signaling. It is believed that cancer cells are particularly sensitive to cell death induced by tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL). However, many cancer cells show blocked TRAIL signaling due to up-regulated expression of an...

Journal: :Blood 2000
D Capello U Vitolo L Pasqualucci S Quattrone G Migliaretti L Fassone C Ariatti D Vivenza A Gloghini C Pastore C Lanza J Nomdedeu B Botto R Freilone D Buonaiuto V Zagonel E Gallo G Palestro G Saglio R Dalla-Favera A Carbone G Gaidano

BCL-6 mutations are accumulated during B-cell transit through the germinal center (GC) and provide a histogenetic marker for B-cell tumors. On the basis of a comprehensive analysis of 308 B-cell neoplasms, we (1) expand the spectrum of tumors associated with BCL-6 mutations; (2) corroborate the notion that mutations cluster with GC and post-GC B-cell neoplasms; and (3) identify heterogeneous mu...

Journal: :American journal of clinical pathology 2004
Stephen J Sup Rana Domiati-Saad Todd W Kelley Roxanne Steinle Xinyu Zhao Eric D Hsi

ZAP-70 is a tyrosine kinase expressed in normal T cells and NK cells. Expression of ZAP-70 has been associated with poor prognosis in B-cell chronic lymphocytic leukemia and might be a surrogate marker for immunoglobin heavy chain (IGH) mutational status in that disease. Little is known about ZAP-70 expression in other hematologic malignant neoplasms. We examined 446 specimens representing a ra...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید